45 related articles for article (PubMed ID: 36260984)
1. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
[TBL] [Abstract][Full Text] [Related]
2. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
3. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
Garcia G; Odaimi M
J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
[TBL] [Abstract][Full Text] [Related]
4. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.
Yang SH; Guo JC; Hsu C; Kuo SH; Tien YW; Cheng AL; Yeh KH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):97-105. PubMed ID: 30852003
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
Raggi D; Necchi A; Giannatempo P
Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer.
Awasthi N; Mikels-Vigdal AJ; Stefanutti E; Schwarz MA; Monahan S; Smith V; Schwarz RE
J Cell Mol Med; 2019 Jun; 23(6):3878-3887. PubMed ID: 30941918
[TBL] [Abstract][Full Text] [Related]
8. Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer.
Uprety D
Clin Lung Cancer; 2019 Mar; 20(2):63-65. PubMed ID: 30545572
[No Abstract] [Full Text] [Related]
9. Leveraging immunochemotherapy for treating pancreatic cancer.
Dongre A; Weinberg RA
Cell Res; 2021 Dec; 31(12):1228-1229. PubMed ID: 34667266
[No Abstract] [Full Text] [Related]
10. Retraction Note: ITGA3 acts as a purity-independent biomarker of both immunotherapy and chemotherapy resistance in pancreatic cancer: bioinformatics and experimental analysis.
Zheng X; Du Y; Liu M; Wang C
Funct Integr Genomics; 2024 May; 24(3):86. PubMed ID: 38730051
[No Abstract] [Full Text] [Related]
11. Pancreatic cancer epigenetics: adaptive metabolism reprograms starving primary tumors for widespread metastatic outgrowth.
Torres AJF; Duryea J; McDonald OG
Cancer Metastasis Rev; 2023 Jun; 42(2):389-407. PubMed ID: 37316634
[TBL] [Abstract][Full Text] [Related]
12. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
Stouten I; van Montfoort N; Hawinkels LJAC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
[TBL] [Abstract][Full Text] [Related]
13. Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
Lin D; Nguyen H; Shah R; Qiao Y; Hartman J; Sugarman R
Gastric Cancer; 2023 May; 26(3):415-424. PubMed ID: 36943511
[TBL] [Abstract][Full Text] [Related]
14. Early Diagnosis of Pancreatic Cancer: Clinical Premonitions, Timely Precursor Detection and Increased Curative-Intent Surgery.
Søreide K; Ismail W; Roalsø M; Ghotbi J; Zaharia C
Cancer Control; 2023; 30():10732748231154711. PubMed ID: 36916724
[TBL] [Abstract][Full Text] [Related]
15. Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?
Melief CJM
Cell Rep Med; 2022 Oct; 3(10):100788. PubMed ID: 36260984
[TBL] [Abstract][Full Text] [Related]
16. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Padrón LJ; Maurer DM; O'Hara MH; O'Reilly EM; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Yu JX; Pfeiffer SM; Spasic M; Xu J; Gherardini PF; Karakunnel J; Mick R; Alanio C; Byrne KT; Hollmann TJ; Moore JS; Jones DD; Tognetti M; Chen RO; Yang X; Salvador L; Wherry EJ; Dugan U; O'Donnell-Tormey J; Butterfield LH; Hubbard-Lucey VM; Ibrahim R; Fairchild J; Bucktrout S; LaVallee TM; Vonderheide RH
Nat Med; 2022 Jun; 28(6):1167-1177. PubMed ID: 35662283
[TBL] [Abstract][Full Text] [Related]
17. Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma.
Saung MT; Zheng L
Ann Pancreat Cancer; 2019 Dec; 2():. PubMed ID: 32405624
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
